›Pain control pathway
›NSAIDs first line
›Ketorolac IV
›10 mg to 30 mg single dose based on local protocol and renal risk
›Avoid if significant AKI or high GI bleed risk
›Ibuprofen PO
›400 mg to 600 mg every 6 to 8 hours as needed
›Max daily dose per local policy
›Evidence
›NSAIDs reduce ureteral smooth muscle spasm and renal pelvic pressure
›ACEP Level B recommendation for NSAIDs as first line analgesia when no contraindication
›Opioid rescue
›Morphine IV
›Initiate 0.05 mg/kg
›Titrate 2 mg every 5 to 10 minutes to analgesic goal
›Monitor respiratory rate and oxygen saturation
›Hydromorphone IV
›Initiate 0.5 mg
›Titrate 0.2 mg to 0.5 mg every 10 minutes to analgesic goal
›Higher risk oversedation in opioid naive
›Discharge opioid strategy
›Lowest effective dose and quantity
›Avoid co prescription with sedatives
›Adjuncts
›Acetaminophen PO or IV
›1000 mg single dose
›Max daily dose per local policy
›Antispasmodics
›Limited evidence for routine use
›Avoid delaying definitive analgesia
Antiemetics and hydration
›Nausea and fluids
›Antiemetics
›Ondansetron IV
›4 mg single dose
›Repeat 4 mg after 15 to 30 minutes if persistent
›Metoclopramide IV
›10 mg single dose
›Avoid in prior dystonic reaction risk
›Fluids
›Isotonic crystalloid bolus
›10 mL/kg if dehydration
›Avoid forced diuresis for stone passage
›Oral hydration
›Encourage once nausea controlled
Medical expulsive therapy
›MET strategy
›Alpha blocker option
›Tamsulosin PO
›0.4 mg daily
›Best evidence for distal ureteral stones
›Counsel orthostasis risk
›Selection
›Distal ureteral stones most responsive
›Larger stones more likely to benefit than very small stones
›Evidence framing
›Mixed trial results
›Use when benefits outweigh risks and follow up is reliable
Infection and obstructed infected system
›Antibiotics and source control
›Suspected pyelonephritis without obstruction
›Antibiotic selection guided by local resistance
›Urine culture guided adjustment
›Suspected infected obstruction
›Initiate antibiotics immediately
›Ceftriaxone IV
›1 g to 2 g daily
›Dose selection per severity and local protocol
›Piperacillin tazobactam IV
›4.5 g every 6 to 8 hours
›Use in severe sepsis or resistant risk
›Allergy alternative
›Consult local stewardship
›Avoid delays to decompression planning
›Decompression
›Ureteral stent option
›Preferred when anatomy allows
›Rapid relief of obstruction
›Percutaneous nephrostomy option
›Alternative when stent not feasible
›Useful in severe infection
›Evidence and recommendations
›Consensus based Class I recommendation for urgent decompression plus antibiotics
›Do not discharge suspected infected obstruction
Definitive stone management triggers
›Procedure planning
›Likely spontaneous passage
›Small distal ureteral stones higher passage probability
›Pain controlled and no infection supports outpatient trial
›Low passage probability
›Large stone size
›Proximal location
›Persistent obstruction
›Urology interventions
›Ureteroscopy
›Definitive removal
›Stent placement common
›Shock wave lithotripsy
›Selected stones and anatomy
›Not for pregnancy
›Percutaneous nephrolithotomy
›Large renal stones
›Higher complication profile